Goldman Sachs Group Inc. raised its holdings in shares of Galapagos NV (NASDAQ:GLPG) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 202,173 shares of the biotechnology company’s stock after acquiring an additional 1,235 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Galapagos NV were worth $15,471,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of the business. Bain Capital Public Equity Management LLC increased its holdings in Galapagos NV by 30.3% during the 2nd quarter. Bain Capital Public Equity Management LLC now owns 71,136 shares of the biotechnology company’s stock valued at $5,443,000 after acquiring an additional 16,536 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Galapagos NV during the 2nd quarter valued at about $237,000. Citadel Advisors LLC increased its holdings in Galapagos NV by 302.0% during the 2nd quarter. Citadel Advisors LLC now owns 11,155 shares of the biotechnology company’s stock valued at $854,000 after acquiring an additional 8,380 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Galapagos NV by 49.5% during the 2nd quarter. Renaissance Technologies LLC now owns 465,300 shares of the biotechnology company’s stock valued at $35,605,000 after acquiring an additional 154,100 shares in the last quarter. Finally, Advisor Group Inc. increased its holdings in Galapagos NV by 233.7% during the 2nd quarter. Advisor Group Inc. now owns 3,090 shares of the biotechnology company’s stock valued at $236,000 after acquiring an additional 2,164 shares in the last quarter. Hedge funds and other institutional investors own 23.62% of the company’s stock.

Shares of Galapagos NV (NASDAQ GLPG) opened at 101.55 on Monday. Galapagos NV has a one year low of $57.16 and a one year high of $104.12. The stock’s 50 day moving average is $101.61 and its 200-day moving average is $101.61. The stock’s market capitalization is $5.17 billion.

COPYRIGHT VIOLATION NOTICE: “Goldman Sachs Group Inc. Acquires 1,235 Shares of Galapagos NV (GLPG)” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/goldman-sachs-group-inc-acquires-1235-shares-of-galapagos-nv-glpg/1634362.html.

Several research firms have weighed in on GLPG. Stifel Nicolaus raised their target price on shares of Galapagos NV from $101.00 to $120.00 and gave the company a “buy” rating in a report on Friday, September 15th. Morgan Stanley reiterated an “overweight” rating and set a $92.00 price target on shares of Galapagos NV in a report on Thursday, August 10th. Janney Montgomery Scott upgraded shares of Galapagos NV from a “sell” rating to a “neutral” rating in a report on Friday, July 7th. They noted that the move was a valuation call. Cowen and Company reiterated a “buy” rating on shares of Galapagos NV in a report on Thursday, August 10th. Finally, BidaskClub upgraded shares of Galapagos NV from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $108.14.

Galapagos NV Profile

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Institutional Ownership by Quarter for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with Analyst Ratings Network's FREE daily email newsletter.